PTEN undergoes widespread functional inactivation in human cancer including GBM, melanoma, prostate adenocarcinoma (PRAD), and uterine corpus endothelial carcinoma (UCEC) through deletions, somatic mutations, and epigenetic silencing (hypermethylation of PTEN promoter) (32–36). The gene discussed is PTEN; the disease is cancer.